Allergan, Inc. (NYSE:AGN): A Catalyst-Rich 2014 On Anvil
February 28, 2014
Allergan, Inc. (NYSE:AGN) should have a catalyst-rich 2014. The specialty drug maker has two new approvals on tap for the first half 2014 (Ozurdex DME and Levadex). Moreover, there is likelihood DARPin moves to Phase III in late 2014, and Allergan should continue to have positive momentum. read on...
U.S. Stocks End Flat Amid Greece Worries, Sales Data; Hot Stocks: YHOO, KORS, RAX, HSP, MAS, GT
Publish Date: Tuesday, February 14, 2012
Stocks(s): GT, HSP, KORS, MAS, MET, RAX, YHOO, ZNGA